Home › NDC Lookup › RxCUI directory › RxCUI 2631788

4.4 ML aprepitant 7.2 MG/ML Injection [Aponvie] — RxCUI 2631788

RxNorm drug concept · Semantic branded drug
RxCUI 2631788 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2631788
Official name4.4 ML aprepitant 7.2 MG/ML Injection [Aponvie]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known as4.4 ML Aponvie 7.2 MG/ML Injection; APONVIE 32 MG in 4.4 ML Injection; Aponvie 32 MG per 4.4 ML Injection
FDA products mapped1
Package NDCs mapped1
Reported Medicaid activity (SDUD)1,165 prescriptions · 9 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Aprepitant: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Aprepitant is designed to prevent nausea and vomiting before they start — not to treat them once they've kicked in. It's given as part of a combination of anti-nausea medicines, us...
  • What exactly is this medicine supposed to do for me?
  • Not without a backup plan. Aprepitant can reduce how well hormonal birth control works — that includes the pill, the patch, implants, and some IUDs. This effect can last for a full...
  • Can I take my birth control as usual while I'm on this?
📖 Read our full Aprepitant guide →

🕸️ Concept Web — How 4.4 ML aprepitant 7.2 MG/ML Injection [Aponvie] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept 4.4 ML aprepitant 7.2 MG/ML Injection [Aponvie] RxCUI 2631788

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Aprepitant 358255
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Aponvie 2631784
  3. Dose forms 6

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Aprepitant Injection 1995149
    • Aprepitant Injectable Product 1995148
    • Aprepitant Injection [Aponvie] 2631787
    • Aponvie Injectable Product 2631786
    • Injection 1649574
    • Injectable Product 1151126
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 11 of 11 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Brand-Name Concepts

  • Aprepitant 7.2 MG/ML [Aponvie] SBDC · 2631785
  • Aprepitant Injection [Aponvie] SBDF · 2631787
  • Aponvie Injectable Product SBDG · 2631786
  • Aponvie BN · 2631784

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 2631788 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
47426-0401-10 10 VIAL, GLASS in 1 CARTON (47426-401-10) / 4.4 mL in 1 VIA... APONVIE Heron Therapeutics, Inc. 2023-03-06
Observed labelers: Heron Therapeutics, Inc. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🧾 Billing Codes (HCPCS)

Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.
CodeDescriptorMapped packagesSources
J8502 Inj, aponvie, 1 mg 1 CMS
⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.